ES2426196T3 - Uso de TSG-6 para el tratamiento de la osteoporosis - Google Patents

Uso de TSG-6 para el tratamiento de la osteoporosis Download PDF

Info

Publication number
ES2426196T3
ES2426196T3 ES07712838T ES07712838T ES2426196T3 ES 2426196 T3 ES2426196 T3 ES 2426196T3 ES 07712838 T ES07712838 T ES 07712838T ES 07712838 T ES07712838 T ES 07712838T ES 2426196 T3 ES2426196 T3 ES 2426196T3
Authority
ES
Spain
Prior art keywords
tsg
polypeptide
seq
polynucleotide
opg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07712838T
Other languages
English (en)
Spanish (es)
Inventor
Afsie Sabokbar
Anthony Day
Caroline Milner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
University of Manchester
Original Assignee
Oxford University Innovation Ltd
University of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd, University of Manchester filed Critical Oxford University Innovation Ltd
Application granted granted Critical
Publication of ES2426196T3 publication Critical patent/ES2426196T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES07712838T 2006-03-06 2007-03-06 Uso de TSG-6 para el tratamiento de la osteoporosis Active ES2426196T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0604460.6A GB0604460D0 (en) 2006-03-06 2006-03-06 Treatment
GB0604460 2006-03-06
PCT/GB2007/000772 WO2007101988A2 (en) 2006-03-06 2007-03-06 Use of tsg-6 for treating bone diseases

Publications (1)

Publication Number Publication Date
ES2426196T3 true ES2426196T3 (es) 2013-10-21

Family

ID=36219200

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07712838T Active ES2426196T3 (es) 2006-03-06 2007-03-06 Uso de TSG-6 para el tratamiento de la osteoporosis

Country Status (7)

Country Link
US (1) US9066908B2 (enExample)
EP (1) EP2001499B1 (enExample)
JP (1) JP5346216B2 (enExample)
DK (1) DK2001499T3 (enExample)
ES (1) ES2426196T3 (enExample)
GB (1) GB0604460D0 (enExample)
WO (1) WO2007101988A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609334B2 (en) 2008-05-29 2013-12-17 The Regents Of The University Of California Biomarkers for painful intervertebral discs and methods of use thereof
WO2015094846A2 (en) * 2013-12-18 2015-06-25 The Texas A&M University System Treatment of gum diseases and gum disorders with tsg-6 protein
GB201910645D0 (en) * 2019-07-25 2019-09-11 Univ Manchester Treatment for dry eye disease
CN111273029B (zh) * 2020-02-25 2023-03-31 芜湖天明生物技术有限公司 rhTSG-6双抗体夹心ELISA法定量检测试剂盒及其使用方法和应用
GB202416087D0 (en) * 2024-10-31 2024-12-18 Link Biologics Treatment of ocular disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
WO1992012175A1 (en) * 1991-01-14 1992-07-23 New York University Cytokine-induced protein, tsg-6, dna coding therefor and uses thereof
EP0705842A2 (en) 1994-10-06 1996-04-10 Hoechst Aktiengesellschaft Regulated genes by stimulation of chondrocytes with 1L-1beta
AU6590896A (en) 1995-07-20 1997-02-18 New York University Pharmaceutical compositions containing tsg-6 for treating inflammatory diseases and cancer-related pathologies and methods
EP1002132A4 (en) * 1997-08-05 2005-04-27 Human Genome Sciences Inc 90 HUMAN SECRETED PROTEINS
DE60235418D1 (de) 2001-04-03 2010-04-01 Nestle Sa Osteoprotegerin in Milch
ITRM20030595A1 (it) 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso della ptx3 o di un suo derivato funzionale da sola o in associazione con tsg6 per il trattamento di patologie degenarative dell'osso o della cartilagine e per il trattamento della infertilita' femminile.

Also Published As

Publication number Publication date
EP2001499A2 (en) 2008-12-17
WO2007101988A2 (en) 2007-09-13
WO2007101988A3 (en) 2007-11-01
US9066908B2 (en) 2015-06-30
EP2001499B1 (en) 2013-06-05
JP5346216B2 (ja) 2013-11-20
JP2009532334A (ja) 2009-09-10
US20090099084A1 (en) 2009-04-16
GB0604460D0 (en) 2006-04-12
DK2001499T3 (da) 2013-09-08

Similar Documents

Publication Publication Date Title
ES2426352T3 (es) Uso de la endoglucosidasa EndoS para el tratamiento de enfermedades mediadas por la inmunoglobulina G
ES2380950T3 (es) Uso de la proteinasa IdeS ( de S, pyogenes) para tratar enfermedades autoinmunitarias y rechazo de injerto
Gabay et al. IL-1 pathways in inflammation and human diseases
US11591378B2 (en) Polypeptides for inhibiting complement activation
ES2281341T3 (es) Lectina humana recombinante que se une a manano.
EP2892547B1 (en) A dominant negative tnf-alpha inhibitor for use in treating neurological disorders of the cns
ES2275304T3 (es) Nuevas composiciones de delta-3 humana y usos diagnosticos y terapeuticos para las mismas.
US9878003B2 (en) Method of treating bone disorders using TSG-6
US8497349B2 (en) Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation
ES2589630T3 (es) OmCI modificado como inhibidor del complemento
US9066908B2 (en) Method of treating bone disorders using TSG-6
KR102221041B1 (ko) 신증후군 및 관련 병태의 치료 방법
US20140088015A1 (en) Mucin 3 EGF-like Domains
ES2432082T3 (es) Uso de la variante de corte y empalme MGF del factor de crecimiento I similar a la insulina para la prevención del daño miocárdico
ES2575517T3 (es) Péptidos de unión a FGF2 y usos de los mismos
CN102675422A (zh) 抗乙型肝炎病毒x蛋白多肽药物
EP1967210A1 (en) Novel application of apelin
CN119161448B (zh) 一种mdga2靶向多肽及其应用
BG67190B1 (bg) Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон
JP2013531990A (ja) アテローム性動脈硬化症治療のための組成物および方法
KR20060136385A (ko) 긴 펜트락신 ｐｔｘ３의 억제제를 포함하는 약제